News

According to the company, this needle will be the thinnest needle of any injectable disease-modifying therapy for people with multiple sclerosis (MS). The needle is said to be

According to Xoma, the new programs add to the multiple discovery and development programs already being advanced through the collaboration. Xoma said that, in collaboration with a number

Under the terms of the partnership, LibraGen will use its proprietary enzyme discovery and development to identify new enzymes for efficient conversion of a large spectrum of ketons

National Institute of Allergy and Infectious Disease (NIAID) is part of the National Institutes of Health (NIH), and its grants are typically given to high-priority NIH programs. The

Under the terms of the amended agreement, EpiCept has granted Durect royalty-free, fully paid up, perpetual and irrevocable rights to the intellectual property licensed as part of the

The new division’s first priority will be to develop over-the-counter wound treatment applications for Oxycyte. Oxycyte is the company’s perfluorocarbon therapeutic oxygen carrier. Dr Diegelmann is a tenured

The transaction was approved by the unanimous vote of Ariad’s independent and disinterested board members, and is effective immediately. Under the terms of the merger agreement, each outstanding

As part of the controlled launch for the AcrySof phakic lens, Alcon will provide surgeons with an integrated and comprehensive training, educational, and support program. Bill Barton, vice

Under the memorandum of understanding (MoU), Siloam Hospitals and Varian have agreed to pursue a collaborative relationship to explore opportunities for developing innovative health solutions for delivering cancer